Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis 2023;82:515-26. doi: 10.1136/ard-2022-223595
Although the results were presented correctly, the summary in the discussion needs to be corrected:
‘Most fungal infections with bimekizumab were mild to moderate, and none were systemic or led to treatment discontinuation.’
‘Most cases of fungal infections with bimekizumab were mild to moderate, with only 2 leading to discontinuation, and no systemic fungal infections were reported.’